Related Experiment Video
Updated: Apr 15, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery
Jinggang Xia1, Yang Qu, Chunlin Yin
1Department of Cardiology, Xuanwu Hospital, Capital Medical University, Beijing, PR China.
Insights
Preoperative rosuvastatin therapy protected cardiac health in patients with coronary artery disease undergoing emergency surgery. This treatment reduced myocardial necrosis and major adverse cardiovascular and cerebrovascular events (MACCE).
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Pharmacology
Background:
- Patients with coronary artery disease (CAD) undergoing emergency noncardiac surgery face elevated cardiovascular risks.
- Long-term statin therapy is common in CAD patients but its perioperative role in emergency settings requires further investigation.
Purpose of the Study:
- To determine if preoperative rosuvastatin administration could protect cardiac health in patients with CAD undergoing emergency noncardiac surgery.
Main Methods:
- A randomized controlled trial involving 550 patients with stable CAD on long-term statin therapy undergoing emergency noncardiac surgery.
- Patients were randomized to receive preoperative rosuvastatin or a placebo (control group).
- All patients received rosuvastatin post-surgery; outcomes assessed included myocardial necrosis and major adverse cardiovascular and cerebrovascular events (MACCE) at 30 days and 6 months.
Main Results:
- Lower incidence of creatinine kinase-myocardial band (CK-MB) elevations at 12 and 24 hours post-surgery in the rosuvastatin group (p = 0.029).
- Significantly reduced incidence of MACCE in the rosuvastatin group compared to the control group (p = 0.019), primarily driven by a decrease in perioperative myocardial infarction (p = 0.029).
- Multivariable analysis indicated a 52% reduction in MACCE incidence at 6 months with rosuvastatin reload therapy (p = 0.03).
Conclusions:
- Preoperative rosuvastatin reload therapy is effective in reducing myocardial necrosis.
- This strategy significantly decreases major adverse cardiovascular and cerebrovascular events (MACCE) following emergency noncardiac surgery in patients with stable CAD on long-term statin therapy.
Objectives:
We explored whether preoperative rosuvastatin could protect the cardiac health of patients with coronary artery disease undergoing emergency, noncardiac surgery.
Methods:
We randomized 550 noncardiac emergency surgery patients with stable coronary artery disease on long-term statin therapy to treatment with and without preoperative rosuvastatin. All patients received rosuvastatin after surgery. We evaluated the incidence of myocardial necrosis and major adverse cardiovascular and cerebrovascular events (MACCE) 30 days and 6 months after surgery.
Results:
Creatinine kinase-myocardial band (CK-MB) isoform elevations occurred less frequently 12 and 24 h after noncardiac emergency surgery in the experimental group than in the control group (p = 0.029). After surgery, the incidence of MACCE was also lower in the experimental group than in the control group (p = 0.019). The difference was mainly due to the incidence of perioperative myocardial infarction (p = 0.029). Multivariable analysis found that rosuvastatin reload reduced the incidence of MACCE 52% 6 months after surgery (p = 0.03).
Conclusions:
Preoperative rosuvastatin reload therapy decreases the incidence of myocardial necrosis and MACCE after noncardiac emergency surgery in patients with stable coronary artery disease on long-term statin therapy.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Acute Coronary Syndrome IV: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview

